Herceptin News and Research

RSS

A new test could save arthritis patients time, money, and pain. But will it be used?

Erinn Maury knew Remicade wasn't the right drug for Patti Schulte, a rheumatoid arthritis patient the physician saw at her Millersville, Maryland, practice. Schulte's swollen, painful joints hadn't responded to Enbrel or Humira, two drugs in the same class.

20 Dec 2023

New drug combo fights breast cancer with brain metastases

A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival among patients with unresectable locally advanced or metastatic HER2-positive breast cancer, compared with T-DM1 alone, according to results from the HER2CLIMB-02 trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.

6 Dec 2023

Precision oncology therapies account for nearly half of new cancer drug approvals since 1998

Of the 198 new oncology drugs approved by the U.S. Food and Drug Administration (FDA) between 1998 and 2022, approximately 43% were precision oncology therapies, the use of which is guided by biomarker testing.

18 Oct 2023

New targeted therapy zolbetuximab extends survival for patients with advanced gastric cancer

An international phase 3 clinical trial, done in participation with Weill Cornell Medicine and NewYork-Presbyterian, found that a new targeted treatment called zolbetuximab, given in combination with a standard chemotherapy, extended survival for patients with advanced gastric or gastroesophageal junction cancer that overexpressed a specific biomarker.

23 Aug 2023

UK oncologists and cardiologists collaborate to prevent chemo-induced cardiomyopathy in cancer patients

Ever since she was 12 years old, Barbie Johnson has been a Kentucky girl at heart. Raised in the bluegrass, Barbie has worked at UK HealthCare for 18 years, first in gynecologic oncology and now in surgery scheduling.

26 Jan 2023

Immune system B-cells may be better in predicting HER2-positive breast cancer treatment response

Researchers at UNC Lineberger Comprehensive Cancer Center and colleagues have found that measuring activation of immune-system B cells may be better than measuring either T-cell activation or the total number of immune cells in and around a tumor, called tumor-infiltrating lymphocytes (TILs), in predicting whether HER2-positive breast cancer responds to treatment.

5 Jan 2023

Alternative approaches to functional and phenotypic assays using multi-parameter flow cytometry

Synexa is an industry-leading biomarker and large molecule bio analytic research service provider. In this interview, NewsMedical speaks with Natalie Strickland, a principal scientist at Synexa, about alternative approaches to flow cytometry.

From Synexa Life Sciences BV 5 Sep 2022

'Crown-like structures' surrounding breast tumors could hinder treatment response, study finds

A new study from the University of Southampton has discovered that 'crown-like structures' surrounding breast tumors in overweight and obese patients could hinder their response to therapy.

24 May 2022

bit.bio expands Board of Directors with appointment of entrepreneurs and Nobel Laureate

Today bit.bio welcomed three new members to its Board of Directors, who bring their respective experience of turning world-class science into new industries.

From bit.bio 27 Oct 2021

MR-guided focused ultrasound can safely deliver antibody therapy to Her2-positive brain metastases

In a first-in-world clinical trial, researchers at Sunnybrook Health Sciences Centre in Toronto, Canada, have demonstrated that magnetic resonance (MR)-guided focused ultrasound can be used to safely deliver antibody therapy to breast cancer that has metastasized to the brain.

13 Oct 2021

Research points the way to identifying new precision treatments for cancer

Researchers at University of California San Diego and University of California San Francisco have mapped out how hundreds of mutations involved in two types of cancer affect the activity of discrete groups of proteins that are the ultimate actors behind the disease.

30 Sep 2021

New technology tricks tumors to eliminate itself through the production of anti-cancer agents

Scientists at the University of Zurich have modified a common respiratory virus, called adenovirus, to act like a Trojan horse to deliver genes for cancer therapeutics directly into tumor cells. Unlike chemotherapy or radiotherapy, this approach does no harm to normal healthy cells.

18 May 2021

New publication details strengths and weaknesses of the U.S. health insurance system

A landmark work that details the strengths and weaknesses of the U.S. health insurance system, including how it lags behind those of other wealthy countries in measures that include mortality from both preventable and treatable causes, has been published.

12 May 2021

Herceptin News and Research

A new test could save arthritis patients time, money, and pain. But will it be used?

New drug combo fights breast cancer with brain metastases

Precision oncology therapies account for nearly half of new cancer drug approvals since 1998

New targeted therapy zolbetuximab extends survival for patients with advanced gastric cancer

UK oncologists and cardiologists collaborate to prevent chemo-induced cardiomyopathy in cancer patients

Immune system B-cells may be better in predicting HER2-positive breast cancer treatment response

Alternative approaches to functional and phenotypic assays using multi-parameter flow cytometry

'Crown-like structures' surrounding breast tumors could hinder treatment response, study finds

bit.bio expands Board of Directors with appointment of entrepreneurs and Nobel Laureate

MR-guided focused ultrasound can safely deliver antibody therapy to Her2-positive brain metastases

Research points the way to identifying new precision treatments for cancer

New technology tricks tumors to eliminate itself through the production of anti-cancer agents

New publication details strengths and weaknesses of the U.S. health insurance system

The Christie NHS Foundation Trust first to offer treatment in cancer patients’ homes

New machine learning method for designing more effective antibody drugs

Discovery offers novel possibilities to target drug-resistant HER2-positive cancers

SORLA protein promotes the growth of breast cancer brain metastasis

Cancer Research UK announces dramatic cuts to its life-saving research budget

Researchers develop first report card on biosimilars for three blockbuster cancer drugs

Targeted therapy may increase overall survival in patients with pancreatic cancer

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News